Ocular manifestations in Sjögren’s syndrome – it never rains but it pours? Case report
More details
Hide details
Studenckie Koło Naukowe przy Klinice Okulistyki Katedry Okulistyki, Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach
Klinika Okulistyki, Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach
Oddział Okulistyki Dorosłych, Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskiego, Śląski Uniwersytet Medyczny w Katowicach
Corresponding author
Anna M. Hitnarowicz   

Studenckie Koło Naukowe przy Klinice Okulistyki Katedry Okulistyki, Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, ul. Ceglana 35, 40-514 Katowice
Ann. Acad. Med. Siles. 2023;77:108–114
Sjögren’s syndrome (SS) is a chronic, systemic, autoimmune inflammatory disease. It is characterized by inflammatory lymphocytic infiltration of exocrine glands, leading to their significant dysfunction and destruction. Lacrimal and salivary glands are commonly affected, causing dryness of the eyes and mouth. The subject of the study is a case report of a 64-year-old woman who had been suffering from discomfort in her right eye for 6 years. Early stage cataract in both eyes, corneal ulceration of the right eye, and a right lower eyelid entropion requiring surgical intervention, were diagnosed at that time. Despite successful treatment, the eyelashes began to grow improperly again and irritated the cornea. Subsequently, the problem of trichiasis also affected the eyelid of the left eye. The eyelashes of both eyes were removed mechanically many times. Sjögren’s syndrome was diagnosed on the basis of the symptoms, a positive Schirmer test and the presence of SS-A antibodies. In the following years, the patient developed keratopathy with corneal epithelial defects, advanced stage cataract, and upper eyelid entropion with associated trichiasis in both eyes. These conditions required both intensive pharmacological and surgical treatment, including an amniotic membrane transplant onto the surface of the right eye, blepharoplasty, lacrimal puncta closure and cataract surgery. Despite the treatment, the patient currently has numerous conjunctival adhesions and vascularized corneal leucoma of the right eye. In addition to the ocular symptoms, the patient has presented other systemic signs.
Thorne I., Sutcliffe N. Sjögren’s syndrome. Br. J. Hosp. Med. (Lond). 2017; 78(8): 438–442, doi: 10.12968/hmed.2017.78.8.438.
Brito-Zerón P., Baldini C., Bootsma H., Bowman S.J., Jonsson R., Mariette X. i wsp. Sjögren syndrome. Nat. Rev. Dis. Primers 2016; 2: 16047, doi: 10.1038/nrdp.2016.47.
Ejma M., Madetko N., Waliszewska-Prosół M. Neurologiczne powikła-nia zespołu Sjögrena. Pol. Przegl. Neurol. 2017; 13(3): 120–131.
Saldanha I.J., Bunya V.Y., McCoy S.S., Makara M., Baer A.N., Akpek E.K. Ocular manifestations and burden related to Sjögren’s syndrome: Results of a patient survey. Am. J. Ophthalmol. 2020; 219: 40–48, doi: 10.1016/j.ajo.2020.05.043.
Stefanski A.L., Tomiak C., Pleyer U., Dietrich T., Burmester G.R., Dörner T. The diagnosis and treatment of Sjögren’s syndrome. Dtsch. Arztebl. Int. 2017; 114(20): 354–361, doi: 10.3238/arztebl.2017.0354.
Akpek E.K., Mathews P., Hahn S., Hessen M., Kim J., Grader-Beck T. i wsp. Ocular and systemic morbidity in a longitudinal cohort of Sjögren’s syndrome. Ophthalmology 2015; 122(1): 56–61, doi: 10.1016/j.ophtha.2014.07.026.
Vivino F.B. Sjogren’s syndrome: Clinical aspects. Clin. Immunol. 2017; 182: 48–54, doi: 10.1016/j.clim.2017.04.005.
Nocturne G. Sjögren’s syndrome update: Clinical and therapeutic aspects. [Article in French]. Rev. Med. Interne. 2019; 40(7): 433–439, doi: 10.1016/j.revmed.2019.03.329.
Kucharz E.J. Zespół Sjögrena. W: M. Olesińska [red.]. Reumatologia w gabinecie lekarza Podstawowej Opieki Zdrowotnej. Wyd. Lekarskie PZWL. Warszawa 2020, s. 359–367.
Akpek E.K., Bunya V.Y., Saldanha I.J. Sjögren’s syndrome: More than just dry eye. Cornea 2019; 38(5): 658–661, doi: 10.1097/ICO.0000000000001865.
Wasielica-Poslednik J., Pfeiffer N., Gericke A. Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren’s syndrome-related keratopathy: a case report. J. Med. Case Rep. 2019; 13(1): 21, doi: 10.1186/s13256-018-1916-4.
Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M. i wsp. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017; 69(1): 35–45, doi: 10.1002/art.39859.
Murtagh P., Comer R., Fahy G. Corneal perforation in undiagnosed Sjögren’s syndrome following topical NSAID and steroid drops post routine cataract extraction. BMJ Case Rep. 2018; 2018: bcr2018225428, doi: 10.1136/bcr-2018-225428.
Gonzales J.A., Lietman T.M. Ocular involvement in Sjögren’s syndrome: Advances in therapy. Curr. Treat. Options Rheum. 2018; 4: 99–109, doi: 10.1007/s40674-018-0084-4.
Shafik A., El-Sibai O., Shafik A.A., Mostafa R. Effect of topical esophageal acidification on salivary secretion: identification of the mechanism of action. J. Gastroenterol. Hepatol. 2005; 20(12): 1935–1939, doi: 10.1111/j.1440-1746.2005.04005.x.
Chang C.S., Liao C.H., Muo C.H., Kao C.H. Increased risk of concurrent gastroesophageal reflux disease among patients with Sjögren’s syndrome: A nationwide population-based study. Eur. J. Intern. Med. 2016; 31: 73–78, doi: 10.1016/j.ejim.2016.01.014.
Natalini J.G., Johr C., Kreider M. Pulmonary involvement in Sjögren syndrome. Clin. Chest Med. 2019; 40(3): 531–544, doi: 10.1016/j.ccm.2019.05.002.
Chung A., Wilgus M.L., Fishbein G., Lynch J.P. 3rd. Pulmonary and bronchiolar involvement in Sjogren’s syndrome. Semin. Respir. Crit. Care Med. 2019; 40(2): 235–254, doi: 10.1055/s-0039-1688448.
Cifuentes-González C., Amaris-Martínez S., Reyes-Guanes J., Uribe-Reina P., de-la-Torre A. Ocular Cicatricial Pemphigoid, Sjögren’s Syndrome, and Hashimoto’s Thyroiditis as a Multiple Autoimmune Syndrome: A case report. Eur. J. Ophthalmol. 2022; 32(4): NP52–NP55, doi: 10.1177/1120672121996637.
Seror R., Bowman S.J., Brito-Zeron P., Theander E., Bootsma H., Tzioufas A. i wsp. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1(1): e000022, doi: 10.1136/rmdopen-2014-000022.
Seror R., Ravaud P., Mariette X., Bootsma H., Theander E., Hansen A. i wsp. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann. Rheum. Dis. 2011; 70(6): 968–972, doi: 10.1136/ard.2010.143743.